Ebvallo gets a second US knockback
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
CG Oncology gets an intermediate-risk bladder boost
Readout of the Pivot-006 trial is brought forward by nearly a year.
Christmas oncology roundup
The holiday period included Genmab’s discontinuation of acasunlimab.
Lung toxicity deaths halt ifinatamab
Ideate-Lung02 goes on global clinical hold.
Enhertu completes its front-line march
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
Bristol challenges Adcetris on its own turf
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
FDA red and green lights: November 2025
The agency approved eight oncology products over the month.
